Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,945 total articles
SK hynix (SSNLF) is my preferred memory play over Micron (MU). The company combines aggressive technology roadmaps, improving gross margins from better product mix, and a valuation that still lags Micron despite similar cycle exposure. For disciplined traders, a long position in the ADR provides an asymmetric payoff as the industry enters an invent…
Flagstar looks vulnerable to ongoing deposit and commercial real-estate stress, but capital resilience and the possibility of an outsized recovery in spreads cap the payoff. This trade idea establishes a defined-risk short with a mid-term horizon, clear stop, and pragmatic targets keyed to continued earnings pressure and funding costs.
Lumentum (LITE) sits squarely in the path of hyperscaler capex for AI infrastructure. Strong customer commitments, a meaningful market cap with stretched but defendable fundamentals, and improving technicals make a mid-term long trade attractive. Plan: enter near current levels, limit risk with a tight stop, and target a move above the $900s as man…
NovoCure (NVCR) plunged after a trial-related setback but fundamentals, recent device approvals, and a pending FDA decision on additional TTFields indications in Q4 2026 create a favorable asymmetric risk/reward. Market cap sits near $2.0B, technicals show consolidation, and institutional short interest is elevated — ideal conditions for a discipli…
We reiterate our Buy on Uranium Royalty Company (UROY). Royalty exposure to a tightening uranium market, a capital-light business model and multiple near-term catalysts support upside. We lay out an actionable entry at $1.50, a $3.00 target and a $0.90 stop for a long-term (180 trading days) trade while highlighting the key risks that could derail …
TeraWulf (WULF) has quietly converted a portion of its bitcoin-mining footprint into utility-grade AI hosting capacity and just locked a 20-year, $19B lease with Anthropic for 401 MW. That deal materially improves revenue visibility and margin mix versus peers still concentrated in variable crypto rewards. The stock trades at ~$22.23 today with a m…
RxSight has retraced to the low end of its 52-week range after a year of headline risk and sales variability. With 2025 revenue coming in at $134.5M, accelerating procedure counts, a clean balance sheet (no debt) and attractive valuation versus revenue, a disciplined long trade looking for mean reversion and continued adoption makes sense. This is …
Byrna Technologies can build a compelling less-lethal product, but recent results show the harder job is turning product into repeat retail sales. With Q2 revenue down 43% YoY, a $10.4M impairment and production cuts, the risk-reward today favors a tactical short into weakness. Entry $3.95, stop $5.50, target $2.25 for a mid-term trade around 45 tr…
Stepan Co. looks inexpensive on headline multiples, but weakening earnings, thin recent trading, and rising short interest argue the market still has work to do on the downside. This is a tactical short trade sized for a mid-term horizon with a tight stop and a realistic target around prior support.
Micron is flush with AI-driven demand: record data-center margins, a revenue surge, and strategic auto supply deals. The stock is trading below recent short-term moving averages but fundamentals (free cash flow $26.2B, ROE 50%) argue for a tactical long. This trade sets a clear entry, stop and target for a mid-term swing (45 trading days) while ack…
MDA Space offers a way to play accelerating government and commercial spending on satellites, robotics and space systems. A $620M acquisition of Blue Canyon (06/26/2026) plus a C$688M Canadian contract give MDA direct access to U.S. defense programs and a $3.5B addressable pipeline. The stock is trading below key moving averages after a pullback; w…
Apollo Global Management (APO) trades nearer its 2026 lows but still sits on a $70B market cap with fee-bearing businesses, active deal flow and growing private-credit presence. Short-term headlines around private credit volatility have compressed sentiment and multiples; we view this as an opportunity for a mid-term swing trade that captures multi…
Corcept (CORT) cratered after a Complete Response Letter for relacorilant, but the company is cash-generative, debt-free and has rebuilt market value into 2026 highs. This trade idea buys the pullback/retest of recent strength with a defined stop and a 180-day time frame, accepting headline risk in exchange for 20%+ upside if catalysts materialize.
Viking Therapeutics (VKTX) remains compelling on fundamentals and momentum: a $4.5B market cap, attractive technicals and a late-stage obesity candidate that keeps the stock in play. That said, price action is carving a possible double-top near the 52-week high and short interest is meaningful — so risk management is essential. This is a swing trad…
POET Technologies dropped sharply after a high-profile order cancellation and a flurry of securities-law filings. With a market cap near $1.44B, a large installed technology moat in optical interposers, and technical indicators suggesting oversold conditions, the risk/reward favors a disciplined mid-term long. Trade plan, catalysts and clear stop m…
Clorox (CLX) trades near $96 with a 5.3% yield, a mid-teens P/E, and free cash flow of roughly $380M. Operational noise and a recent portfolio shuffle have pressured the stock; that creates a high-yield entry for investors willing to back brand strength and margin recovery over the next 180 trading days. This note lays out an actionable long trade …
Medtronic is a cash-generating medical-device franchise trading at a modest multiple, supported by AI-enabled surgical growth, a broad product portfolio, and a defensible dividend. This trade idea outlines a long entry at ~$83 with a $100 target over 180 trading days and a $75 stop — a risk-managed way to own a high-quality medtech name while key c…
Envista (NVST) trades at roughly $25.77 with a market cap near $4.19B and a P/E north of 60 despite low ROE/ROA and only modest momentum. The dental equipment and consumables markets are expanding, but Envista's returns and margins look underwhelming relative to investor expectations embedded in the stock price. This trade idea recommends a tactica…
After a brutal drawdown, The Trade Desk is trading like a busted growth name while still generating strong profits and free cash flow. At roughly $9.4B market cap and P/FCF ~11, the company looks reasonably priced if revenue stabilizes and customer retention remains intact. This trade idea targets a rebound driven by reallocation into open-web prog…
TotalEnergies combines integrated oil & gas cash flow with expanding renewables projects and a near-5% yield. At roughly $78 today, valuation (PE ~11.2, PB ~1.36) and technicals arguing for mean reversion, we favor a long trade sized for a medium-risk income-growth sleeve: entry $78.00, target $90.00, stop $72.00, horizon 180 trading days.
Hope Bancorp (HOPE) is trading at a bargain-like price-to-book (0.75) and yields ~4.2%, while improving asset quality and deposit scale from the Territorial Bancorp deal. Higher provisions have compressed near-term earnings, but the risk/reward looks asymmetric for a disciplined swing trade. Entry $13.45, stop $12.00, target $16.50 (mid-term, 45 tr…
Nasdaq is shifting from a pure exchange operator to a recurring-revenue Financial Technology and Capital Access Platforms provider - an 'Access-as-a-Service' (AaaS) pivot that should support higher margins and steadier cash flow. The SpaceX mega-IPO and record Closing Cross volumes are tangible near-term catalysts; regulatory and index-driven liqui…
Newmont (NEM) pulled back sharply in June as gold prices slid and production guidance was trimmed. The market overreacted to a temporary hit to margins — Newmont's balance sheet strength, $9.24B in trailing free cash flow and an enlarged buyback provide a clear buy-the-dip setup. We recommend a tactical long with an explicit entry at $94.00, stop a…
Lucid's recent delivery momentum likely supports a near-term price rebound, but persistent losses, heavy cash burn and fresh securities litigation argue for a tactical, not buy-and-hold, approach. I lay out a mid-term swing trade that captures the bounce while limiting downside if execution or capital questions reappear.
Seanergy has locked in roughly 45% of available operating days in Q2-Q4 2026 at an average gross daily rate of $29,300 and completed fleet renewal moves that materially improve future cash flow visibility. At a market cap of $309m and a PE near 8, the stock offers yield, catalyst-driven upside and a clear risk-managed trade plan.
